Vorinostat and Palliative Radiotherapy

Sponsor
Oslo University Hospital
Study ID
NCT00455351
Phase
PHASE1
Status
Completed

Conditions

  • Pelvic Cancer
  • Radiotherapy

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Phase I study. Side-effects when combined with standard palliative radiotherapy.

Key Dates

Start date
Feb 28, 2007
Status verified
May 2023
Primary completion
Mar 31, 2009
Completion
Aug 31, 2009

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A I
    Study drug

Primary Outcome Measure

DLT [ Time Frame: continously ]

Related Studies